RS60022B1 - 1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitori - Google Patents
1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitoriInfo
- Publication number
- RS60022B1 RS60022B1 RS20200240A RSP20200240A RS60022B1 RS 60022 B1 RS60022 B1 RS 60022B1 RS 20200240 A RS20200240 A RS 20200240A RS P20200240 A RSP20200240 A RS P20200240A RS 60022 B1 RS60022 B1 RS 60022B1
- Authority
- RS
- Serbia
- Prior art keywords
- ezh1
- ezh2 inhibitors
- benzodioxole derivatives
- benzodioxole
- derivatives
- Prior art date
Links
- 150000005529 1,3-benzodioxoles Chemical class 0.000 title 1
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014053235 | 2014-03-17 | ||
PCT/JP2015/057652 WO2015141616A1 (ja) | 2014-03-17 | 2015-03-16 | 1,3-ベンゾジオキソール誘導体 |
EP15765525.9A EP3121175B1 (en) | 2014-03-17 | 2015-03-16 | 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RS60022B1 true RS60022B1 (sr) | 2020-04-30 |
Family
ID=54144584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200240A RS60022B1 (sr) | 2014-03-17 | 2015-03-16 | 1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitori |
Country Status (28)
Country | Link |
---|---|
US (2) | US10017500B2 (sr) |
EP (1) | EP3121175B1 (sr) |
JP (1) | JP5806438B1 (sr) |
KR (1) | KR102302830B1 (sr) |
CN (1) | CN106132954B (sr) |
AU (1) | AU2015232543B2 (sr) |
BR (1) | BR112016020621B1 (sr) |
CA (1) | CA2942883C (sr) |
CY (1) | CY1122821T1 (sr) |
DK (1) | DK3121175T3 (sr) |
ES (1) | ES2774900T3 (sr) |
HR (1) | HRP20200354T1 (sr) |
HU (1) | HUE049417T2 (sr) |
IL (1) | IL247836B (sr) |
LT (1) | LT3121175T (sr) |
MX (1) | MX370676B (sr) |
MY (1) | MY192603A (sr) |
NZ (1) | NZ723312A (sr) |
PH (1) | PH12016501813A1 (sr) |
PL (1) | PL3121175T3 (sr) |
PT (1) | PT3121175T (sr) |
RS (1) | RS60022B1 (sr) |
RU (1) | RU2679131C2 (sr) |
SG (1) | SG11201607006TA (sr) |
SI (1) | SI3121175T1 (sr) |
TW (1) | TWI648275B (sr) |
WO (1) | WO2015141616A1 (sr) |
ZA (1) | ZA201605622B (sr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3121175T3 (da) | 2014-03-17 | 2020-03-09 | Daiichi Sankyo Co Ltd | 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere |
BR112018001688B1 (pt) * | 2015-07-30 | 2023-05-02 | Daiichi Sankyo Company, Limited | Uso de um composto |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
CN106588914B (zh) * | 2015-10-16 | 2018-11-02 | 陈剑 | 具有取代吡啶并咪唑类衍生物,其制备及其在医药上的应用 |
US10759787B2 (en) * | 2015-11-19 | 2020-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
WO2017199227A1 (en) | 2016-05-20 | 2017-11-23 | S & I Ophthalmic, Llc. | Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester |
KR101770302B1 (ko) * | 2016-06-28 | 2017-08-22 | 주식회사 녹십자 | 다이페닐메탄 유도체의 제조방법 |
CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
WO2018119444A1 (en) * | 2016-12-23 | 2018-06-28 | Daiichi Sankyo Company, Limited | Sulfonamide compounds having tnap inhibitory activity |
KR20190105602A (ko) | 2017-01-19 | 2019-09-17 | 다이이찌 산쿄 가부시키가이샤 | Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
EP3615020B1 (en) * | 2017-04-26 | 2024-04-10 | University of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
WO2018210302A1 (zh) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
KR102616949B1 (ko) | 2017-09-14 | 2023-12-22 | 다이이찌 산쿄 가부시키가이샤 | 고리형 구조를 갖는 화합물 |
AU2018363467B2 (en) | 2017-11-10 | 2023-09-07 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing benzofuran derivative |
ES2923290T3 (es) | 2018-01-31 | 2022-09-26 | Mirati Therapeutics Inc | Inhibidores de PRC2 |
KR20210003160A (ko) * | 2018-04-18 | 2021-01-11 | 콘스텔레이션 파마슈티칼스, 인크. | 메틸 변형 효소 조절제, 이의 조성물 및 용도 |
CN112262143A (zh) * | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
KR20210040077A (ko) * | 2018-07-27 | 2021-04-12 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | 다치환 벤젠화합물 및 이의 제조방법 |
KR20210097707A (ko) | 2018-11-29 | 2021-08-09 | 다이이찌 산쿄 가부시키가이샤 | 조합 의약으로서 사용되는 ezh1/2 이중 저해제를 함유하는 의약 조성물 |
KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
BR112022001154A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
CA3148447A1 (en) * | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxa mide |
KR20220044679A (ko) | 2019-08-08 | 2022-04-11 | 다이이찌 산쿄 가부시키가이샤 | 항ccr4 항체 저항성의 암 치료제 |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
CN115175905A (zh) * | 2020-03-13 | 2022-10-11 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
CN116018335A (zh) | 2020-07-08 | 2023-04-25 | 第一三共株式会社 | 用于制备1,3-苯并二氧杂环戊烯衍生物的方法 |
MX2023001603A (es) * | 2020-08-13 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos. |
KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
TW202333702A (zh) * | 2021-11-10 | 2023-09-01 | 日商第一三共股份有限公司 | 具有優異溶出性之醫藥組成物 |
CN114149297A (zh) * | 2021-12-07 | 2022-03-08 | 北京中医药大学 | 一种微波辅助的选择性芳基甲醛的绿色合成方法 |
CN116496263A (zh) * | 2022-01-27 | 2023-07-28 | 江苏天士力帝益药业有限公司 | Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用 |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
CN115974856B (zh) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
CA2854447A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
WO2013075084A1 (en) * | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9562041B2 (en) * | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
US20150272939A1 (en) * | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
SG11201503893RA (en) * | 2012-11-19 | 2015-06-29 | Agency Science Tech & Res | Method of treating cancer |
DK3121175T3 (da) | 2014-03-17 | 2020-03-09 | Daiichi Sankyo Co Ltd | 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere |
-
2015
- 2015-03-16 DK DK15765525.9T patent/DK3121175T3/da active
- 2015-03-16 SI SI201531090T patent/SI3121175T1/sl unknown
- 2015-03-16 HU HUE15765525A patent/HUE049417T2/hu unknown
- 2015-03-16 ES ES15765525T patent/ES2774900T3/es active Active
- 2015-03-16 RS RS20200240A patent/RS60022B1/sr unknown
- 2015-03-16 US US15/123,523 patent/US10017500B2/en active Active
- 2015-03-16 SG SG11201607006TA patent/SG11201607006TA/en unknown
- 2015-03-16 LT LTEP15765525.9T patent/LT3121175T/lt unknown
- 2015-03-16 JP JP2015534847A patent/JP5806438B1/ja active Active
- 2015-03-16 WO PCT/JP2015/057652 patent/WO2015141616A1/ja active Application Filing
- 2015-03-16 KR KR1020167024813A patent/KR102302830B1/ko active IP Right Grant
- 2015-03-16 PT PT157655259T patent/PT3121175T/pt unknown
- 2015-03-16 AU AU2015232543A patent/AU2015232543B2/en active Active
- 2015-03-16 MY MYPI2016001687A patent/MY192603A/en unknown
- 2015-03-16 CA CA2942883A patent/CA2942883C/en active Active
- 2015-03-16 BR BR112016020621-5A patent/BR112016020621B1/pt active IP Right Grant
- 2015-03-16 CN CN201580014878.3A patent/CN106132954B/zh active Active
- 2015-03-16 RU RU2016140420A patent/RU2679131C2/ru active
- 2015-03-16 TW TW104108302A patent/TWI648275B/zh active
- 2015-03-16 MX MX2016011825A patent/MX370676B/es active IP Right Grant
- 2015-03-16 PL PL15765525T patent/PL3121175T3/pl unknown
- 2015-03-16 NZ NZ72331215A patent/NZ723312A/en unknown
- 2015-03-16 EP EP15765525.9A patent/EP3121175B1/en active Active
-
2016
- 2016-08-15 ZA ZA2016/05622A patent/ZA201605622B/en unknown
- 2016-09-15 IL IL247836A patent/IL247836B/en active IP Right Grant
- 2016-09-16 PH PH12016501813A patent/PH12016501813A1/en unknown
-
2018
- 2018-06-07 US US16/002,297 patent/US10954219B2/en active Active
-
2020
- 2020-03-03 HR HRP20200354TT patent/HRP20200354T1/hr unknown
- 2020-03-04 CY CY20201100194T patent/CY1122821T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT3121175T (lt) | 1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai | |
AU2015342774B2 (en) | EZH2 inhibitors and uses thereof | |
ZA201608077B (en) | Combination, composition, and method of administering the combination or composition to animals | |
HK1246273B (zh) | 作為溴域抑制劑的取代吡啶 | |
ZA201704382B (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg | |
IL247822A0 (en) | History of Tubolisin | |
HK1251566A1 (zh) | 作為hdac1/2抑制劑的呱啶衍生物 | |
EP3201187A4 (en) | Compositions and methods for inhibiting bmp | |
EP3122355A4 (en) | Compositions and methods for inhibiting bmp | |
ZA201704116B (en) | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase | |
HRP20182064T1 (hr) | Derivati tetrahidrokinolina kao inhibitori bromodomene | |
ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
PL3142837T3 (pl) | Sposób modyfikacji drewna | |
HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
SG11201607745WA (en) | Compositions and methods for producing chemicals and derivatives thereof | |
PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
PT3166945T (pt) | Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos |